{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:02Z","timestamp":1707524402513},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,10]]},"DOI":"10.7759\/cureus.19446","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T20:22:31Z","timestamp":1636575751000},"source":"Crossref","is-referenced-by-count":0,"title":["Canagliflozin Markedly Decreased Proteinuria in a Patient With IgA Nephropathy"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Aameish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mala A","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Baumstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler DC","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, et al.. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021, 100:215-24. 10.1016\/j.kint.2021.03.033","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15260920","article-title":"Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis","volume":"16","author":"Jardine M","year":"2021","unstructured":"Jardine M, Zhou Z, Lambers Heerspink HJ, et al.. Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis. Clin J Am Soc Nephrol. 2021, 16:384-95. 10.2215\/CJN.15260920","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson A","year":"2019","unstructured":"Thompson A, Carroll K, Inker LA, et al.. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019, 14:469-81. 10.2215\/CJN.08600718","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-02163-3","article-title":"Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report","volume":"21","author":"Huang Y","year":"2020","unstructured":"Huang Y, Li XJ, Li YQ, et al.. Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report. BMC Nephrol. 2020, 21:504. 10.1186\/s12882-020-02163-3","journal-title":"BMC Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2021.05.002","article-title":"IgA nephropathy after SARS-CoV-2 vaccination","volume":"3","author":"Abramson M","year":"2021","unstructured":"Abramson M, Mon-Wei Yu S, Campbell KN, Chung M, Salem F. IgA nephropathy after SARS-CoV-2 vaccination. Kidney Med. 2021, 3:860-3. 10.1016\/j.xkme.2021.05.002","journal-title":"Kidney Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.002","article-title":"Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy","volume":"99","author":"Negrea L","year":"2021","unstructured":"Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int. 2021, 99:1487. 10.1016\/j.kint.2021.03.002","journal-title":"Kidney Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.04.024","article-title":"A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination","volume":"100","author":"Rahim SE","year":"2021","unstructured":"Rahim SE, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int. 2021, 100:238. 10.1016\/j.kint.2021.04.024","journal-title":"Kidney Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar L","year":"2020","unstructured":"Premkumar L, Segovia-Chumbez B, Jadi R, et al.. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020, 5:8413. 10.1126\/sciimmunol.abc8413","journal-title":"Sci Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection [PREPRINT]","author":"Stamatatos L","year":"2021","unstructured":"Stamatatos L, Czartoski J, Wan YH, et al.. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection [PREPRINT]. Science. 2021, eabg9175. 10.1126\/science.abg9175","journal-title":"Science"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/75963-canagliflozin-markedly-decreased-proteinuria-in-a-patient-with-iga-nephropathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:28Z","timestamp":1707507388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/75963-canagliflozin-markedly-decreased-proteinuria-in-a-patient-with-iga-nephropathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.19446","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,10]]}}}